Physician profile
Mark Ryan
NPI 1659513919
$8,064.54
in general payments reported to CMS, 2019-2025
43 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $584 · 2021: $950 · 2022: $1,185 · 2023: $1,161 · 2024: $1,914 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,915.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,469.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $1,087.92 | 2019-2025 | |
| Lilly USA, LLC | $981.51 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $597.28 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $514.02 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $413.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $332.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $326.06 | 2020-2025 | Trelegy Ellipta, Shingrix, Boostrix |
| Novartis Pharmaceuticals Corporation | $232.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.68 | 2021-2025 | Trintellix |
| Corcept Therapeutics | $189.07 | 2021-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $146.86 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.95 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.80 | 2024-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $119.09 | 2022-2024 | Linzess |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $118.87 | 2019-2021 | |
| Dexcom, INC. | $109.51 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $106.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Radius Health, INC. | $78.32 | 2020-2025 | Tymlos |
| Corium, LLC | $62.58 | 2025 | Azstarys |
| Astellas Pharma US INC | $61.57 | 2023-2025 | Veozah, Myrbetriq |
| Irhythm Technologies, INC. | $58.85 | 2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $53.92 | 2020-2024 | |
| Kowa Pharmaceuticals America, INC. | $53.89 | 2021-2025 | Zoryve |
| Antares Pharma, INC. | $47.75 | 2024-2025 | Xyosted |
| Abbott Laboratories | $47.01 | 2022 | |
| Esperion Therapeutics, INC. | $42.93 | 2024 | Nexletol |
| Currax Pharmaceuticals LLC | $40.40 | 2020-2022 | |
| Eisai INC. | $37.96 | 2024 | |
| Vivus LLC | $30.00 | 2020 | |
| Edwards Lifesciences Corporation | $28.89 | 2022 | |
| Endo Pharmaceuticals INC. | $27.56 | 2021 | |
| Boston Scientific Corporation | $27.50 | 2022-2023 | Watchman |
| Becton, Dickinson and Company | $27.45 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.31 | 2021 | |
| Axsome Therapeutics, INC. | $20.83 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $17.53 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $17.05 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.51 | 2025 | Capvaxive |
| Amag Pharmaceuticals, INC. | $13.62 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.55 | 2022 | |
| Viiv Healthcare Company | $13.43 | 2024 | Apretude |
| Inogen, INC. | $6.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.